EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

RASD 2 Drives Renal Clear Cell Carcinoma Progression via RAF 1 (Ser338) Phosphorylation

Jingxuan Yu iD, Gang Yu, Yuan Liu, Yu Zhou, Wei Liu, Lin Wang, Lide Liu, Yan Liu, Tiejun Pan, Zhenyu Liu iD, Lei Gao

Cancer Science · 2026-08 · 117 (8) · 2194-2207

DOI: 10.1111/cas.70415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 01.06.2026. Verfasst von Jingxuan Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Postgraduate Union Training Base of General Hospital of Central Theater Command, School of Medicine, Wuhan University of Scien…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Proto-Oncogene Proteins c-raf. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Hubei Province, Natural Science Foundation Exploration Plan (Morning Light Plan) of Wuhan City, Postdoctoral Scientific Research Foundation, General Hospital of Central Theater Command.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) is a highly aggressive malignancy with limited treatment options. Although RASD2, which encodes a Ras‐related GTP‐binding protein, has been linked to melanoma progression, its role in ccRCC remains unclear. In this study, we systematically investigated the oncogenic functions and mechanisms of RASD2 in ccRCC. Clinically, RASD2 was significantly overexpressed in tumor tissues compared with adjacent normal tissues and correlated with poor patient prognosis. Functional studies demonstrated that RASD2 promotes proliferation, migration, and invasion of the ccRCC cells in vitro, findings further supported by xenograft models in nude mice. Mechanistically, RASD2 activated the P38/ERK–MAPK pathway, and inhibition experiments confirmed its necessity for RASD2‐driven oncogenesis. Through co‐immunoprecipitation and LC–MS/MS, we identified RAF1 as a key binding partner. RASD2 enhanced RAF1 phosphorylation at Ser338, thereby activating the P38/ERK–MAPK pathway. RAF1 phosphorylation at Ser338 was critical for ccRCC cell growth, migration, and invasion. The RAF1 inhibitor BAY43‐9006 reduced p‐RAF1 (Ser338)/RAF1 levels, suppressed ccRCC proliferation, migration, and invasion in vitro, and significantly inhibited tumor growth in vivo. These findings identify RASD2 as a novel oncoprotein that promotes ccRCC tumorigenesis through p‐RAF1 (Ser338)‐mediated P38/ERK–MAPK activation, suggesting RAF1 inhibition as a promising therapeutic strategy for ccRCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsProto-Oncogene Proteins c-rafHumansAnimalsPhosphorylationCell Line, TumorMiceCell ProliferationDisease ProgressionCell MovementMice, NudeMAP Kinase Signaling SystemFemaleMaleGene Expression Regulation, NeoplasticGTPase-Activating Proteins

Stichwörter der Autor:innen

P38/ERK–MAPK signalingRAF1RASD2ccRCC

Substanzen

Proto-Oncogene Proteins c-rafRaf1 protein, humanRASAL2 protein, humanGTPase-Activating Proteins

Autor:innen und Institutionen

  • Department of Urology, Postgraduate Union Training Base of General Hospital of Central Theater Command, School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, China.
  • Department of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
  • Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, Hubei, China.
  • Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
  • General Hospital of Central Theater Command and Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan, Hubei, China.
  • School of Clinical Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China.

ORCID-Profile: Jingxuan Yu, Zhenyu Liu

Förderung

  • Natural Science Foundation of Hubei Province
  • Natural Science Foundation Exploration Plan (Morning Light Plan) of Wuhan City
  • Postdoctoral Scientific Research Foundation, General Hospital of Central Theater Command

Zitieren

APA

Yu, J., Yu, G., Liu, Y., Zhou, Y., Liu, W., Wang, L., Liu, L., Liu, Y., Pan, T., Liu, Z., & Gao, L. (2026). RASD 2 Drives Renal Clear Cell Carcinoma Progression via RAF 1 (Ser338) Phosphorylation. Cancer Science, 117(8), 2194-2207. https://doi.org/10.1111/cas.70415

Vancouver

Yu J, Yu G, Liu Y, Zhou Y, Liu W, Wang L, et al. RASD 2 Drives Renal Clear Cell Carcinoma Progression via RAF 1 (Ser338) Phosphorylation. Cancer Science. 2026;117(8):2194-2207. doi:10.1111/cas.70415

BibTeX
@article{Yu2026,
  author = {Yu, Jingxuan and Yu, Gang and Liu, Yuan and Zhou, Yu and Liu, Wei and Wang, Lin and Liu, Lide and Liu, Yan and Pan, Tiejun and Liu, Zhenyu and Gao, Lei},
  title = {RASD 2 Drives Renal Clear Cell Carcinoma Progression via RAF 1 (Ser338) Phosphorylation},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {8},
  pages = {2194--2207},
  doi = {10.1111/cas.70415}
}
Kostenlos starten →